Tradestie Institutional Equity Comparison Engine

TAK vs VIR โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

TAK Overall Edge

TAK Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while VIR counters with relative strength in Valuation. Fundamentally, TAK trades at 12.7x Forward P/E with 16.6% operating margin (+6.7% YoY revenue) versus VIR at 4.3x Forward P/E and -70.2% operating margin (+19582.5% YoY). In options structure, TAK sits in UNCLASSIFIED (5th %ile IV; Dealer Gamma Walls on Pro) against VIR sits in BREAKDOWN (6th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner VIR
TAK 12.7x vs VIR 4.3x Fwd P/E
Growth & Margin Winner TAK
Op Margin 16.6% vs -70.2% ยท YoY +6.7% vs +19582.5%
Momentum & Technical Winner TAK
1Y +51.8% vs +78.4% ยท 52W Pos 97% vs 49%
Options & Structure Winner TAK
UNCLASSIFIED (5th %ile IV) vs BREAKDOWN (6th %ile IV)
TAK NYSE
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Pharmaceutical Preparations
$21.61
+0.86% 1D
Market Cap $67.5B
1M Return +9.89%
1Y Return +51.79%
Forward P/E 12.7x
Unified AI Score
47.7 / 100 HOLD
Tech 42.0 Fund 43.0 Flow 50.0 Mom 40.0
VIR NASDAQ
Vir Biotechnology, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$9.76
-2.01% 1D
Market Cap $2.1B
1M Return -2.01%
1Y Return +78.43%
Forward P/E 4.3x
Unified AI Score
41.0 / 100 SELL
Tech 26.0 Fund 46.0 Flow 67.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: TAK +51.79% VIR +78.43% Spread: +26.64 pp (VIR Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
TAK TTM Op. Margin: 16.6% VIR TTM Op. Margin: -70.2%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TAK vs VIR. Trailing 12-month operating profitability (TAK 16.6% vs VIR -70.2%) and valuation multiples (TAK 12.7x vs VIR 4.3x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: TAK (7) vs VIR (3)
Institutional Metric TAK VIR Criterion Row Winner
Market Capitalization Scale $67.5B $2.1B Larger Scale TAK
Trailing P/E Ratio Valuation N/M 4.3x Lower Multiple VIR
Forward P/E Ratio Valuation 12.7x 4.3x Lower Multiple VIR
Revenue Growth (YoY) Growth +6.7% +19582.5% Higher Growth VIR
Operating Margin (TTM) Profitability 16.6% -70.2% Higher Margin TAK
Net Profit Margin Profitability 0.9% -61.0% Higher Margin TAK
Return on Equity (ROE) Capital Efficiency 0.6% -21.8% Higher ROE TAK
52-Week Range Position Momentum 97% ($14โ€“$22) 49% ($5โ€“$14) Stronger Trend TAK
Beta / 30D Volatility Risk Regime -0.02ฮฒ ยท 22% Vol 1.71ฮฒ ยท 102% Vol Lower Realized Risk TAK
Unified Institutional Score Composite Signal 47.7 / 100 (HOLD) 41.0 / 100 (SELL) Higher Composite TAK

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full TAK vs VIR Buy Guide
TAK UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 5th %ile
IV Regime Compressed (<25th %ile)
Live TAK Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
VIR BREAKDOWN
5d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live VIR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither TAK nor VIR registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.